New hope for frail lung cancer patients: testing a gentler combo therapy
NCT ID NCT07398560
Summary
This study is testing whether a combination of an immunotherapy drug (adebrelimab) and a milder, oral form of chemotherapy (etoposide) can help control advanced small cell lung cancer in older patients or those who are too frail for standard intensive treatments. It aims to see if this approach is safe and effective at slowing cancer growth and extending life. The trial will enroll about 47 patients who meet specific health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Third Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.